Related Experiment Video
Updated: Jun 28, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Infant Acute Lymphoblastic Leukemia-New Therapeutic Opportunities
Marika Kulczycka1, Kamila Derlatka1, Justyna Tasior1
1Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland.
Insights
Infant acute lymphoblastic leukemia (ALL) presents unique challenges, with KMT2A-rearranged ALL being harder to treat. Novel therapies are crucial for improving outcomes in infants diagnosed with this rare pediatric cancer.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Genetics
Background:
- Infant acute lymphoblastic leukemia (ALL) is a rare pediatric cancer diagnosed in children under one year old.
- It accounts for less than 5% of all pediatric ALL cases.
- Infant ALL has poorer treatment outcomes compared to older children, necessitating new therapeutic strategies.
Purpose of the Study:
- To provide a comprehensive review of infant ALL.
- To synthesize current literature on epidemiology, clinical presentation, and molecular genetics.
- To explore novel therapeutic approaches for infant ALL.
Main Methods:
- Literature review of existing studies on infant ALL.
- Analysis of epidemiological data.
- Synthesis of molecular genetic findings and treatment outcomes.
Main Results:
- Two main subtypes of infant ALL exist: KMT2A-rearranged ALL (difficult to cure) and KMT2A-non-rearranged ALL (better survival).
- Molecularly targeted therapies and immunotherapy show promise for improving treatment.
- Current literature highlights the need for tailored treatment approaches for infants.
Conclusions:
- Infant ALL requires specialized attention due to its distinct characteristics and poorer prognosis.
- Advances in targeted therapies and immunotherapy offer new hope for better outcomes.
- Further research into novel treatment strategies is essential for this vulnerable population.
Abstract:
Infant acute lymphoblastic leukemia (Infant ALL) is a kind of pediatric ALL, diagnosed in children under 1 year of age and accounts for less than 5% of pediatric ALL. In the infant ALL group, two subtypes can be distinguished: KMT2A-rearranged ALL, known as a more difficult to cure form and KMT2A- non-rearranged ALL with better survival outcomes. As infants with ALL have lesser treatment outcomes compared to older children, it is pivotal to provide novel treatment approaches. Progress in the development of molecularly targeted therapies and immunotherapy presents exciting opportunities for potential improvement. This comprehensive review synthesizes the current literature on the epidemiology, clinical presentation, molecular genetics, and therapeutic approaches specific to ALL in the infant population.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...